PT  - JOURNAL ARTICLE
AU  - Azar, Joseph
AU  - Evans, John P.
AU  - Sikorski, Madison
AU  - Chakravarthy, Karthik
AU  - McKenney, Selah
AU  - Carmody, Ian
AU  - Zeng, Cong
AU  - Teodorescu, Rachael
AU  - Song, No Joon
AU  - Hamon, Jamie
AU  - Bucci, Donna
AU  - Velegraki, Maria
AU  - Bolyard, Chelsea
AU  - Weller, Kevin P.
AU  - Reisinger, Sarah
AU  - Bhat, Seema A.
AU  - Maddocks, Kami J.
AU  - Gumina, Richard J.
AU  - Vlasova, Anastasia N.
AU  - Oltz, Eugene M.
AU  - Saif, Linda J.
AU  - Chung, Dongjun
AU  - Woyach, Jennifer A.
AU  - Shields, Peter G.
AU  - Liu, Shan-Lu
AU  - Li, Zihai
AU  - Rubinstein, Mark P.
TI  - Suppression of de novo antibody responses against SARS-CoV2 and the Omicron variant after mRNA vaccination and booster in patients with B cell malignancies undergoing active treatment, but maintenance of pre-existing antibody levels against endemic viruses
AID  - 10.1101/2022.03.17.22272389
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.17.22272389
4099  - http://medrxiv.org/content/early/2022/03/18/2022.03.17.22272389.short
4100  - http://medrxiv.org/content/early/2022/03/18/2022.03.17.22272389.full
AB  - The impact of SARS-CoV2 vaccination in cancer patients remains incompletely understood given the heterogeneity of cancer and cancer therapies. We assessed vaccine-induced antibody response to the SARS-CoV2 Omicron (B.1.1.529) variant in 57 patients with B cell malignancies with and without active B cell-targeted therapy. Ancestral- and Omicron-reactive antibody levels were determined by ELISA and neutralization assays. In over one third of vaccinated patients at the pre-booster timepoint, there were no ELISA-detectable antibodies against either the ancestral strain or Omicron variant. The lack of vaccine-induced antibodies was predominantly in patients receiving active therapy such as anti-CD20 monoclonal antibody (mAb) or Bruton’s tyrosine kinase inhibitors (BTKi). While booster immunization was able to induce detectable antibodies in a small fraction of seronegative patients, the benefit was disproportionately evident in patients not on active therapy. Importantly, in patients with post-booster ELISA-detectable antibodies, there was a positive correlation of antibody levels against the ancestral strain and Omicron variant. Booster immunization increased overall antibody levels, including neutralizing antibody titers against the ancestral strain and Omicron variant; however, predominantly in patients without active therapy. Furthermore, ancestral strain neutralizing antibody titers were about 5-fold higher in comparison with those to Omicron, suggesting that even with booster administration, there may be reduced protection against the Omicron variant. Interestingly, in almost all patients regardless of active therapy, including those unable to generate detectable antibodies against SARS-CoV2 spike, we observed comparable levels of EBV, influenza, and common cold coronavirus reactive antibodies demonstrating that B cell-targeting therapies primarily impair de novo but not pre-existing antibody levels. These findings suggest that patients with B cell malignancies on active therapy may be at disproportionately higher risk to new versus endemic viral infection and suggest utility for vaccination prior to B cell-targeted therapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch reported in this publication was supported by The Ohio State University Comprehensive Cancer Center and the National Institutes of Health under grant number P30 CA016058. S-LL was supported by an NIH grant R01 AI150473, by the National Cancer Institute of the NIH under award no. U54CA260582, and by a fund provided by an anonymous private donor to OSU. JPE was supported by Glenn Barber Fellowship from the Ohio State University College of Veterinary Medicine. MPR was supported by NIH grant R01CA222817.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The samples and data were collected from cancer patients enrolled under an approved IRB protocol (part of the SIIREN study) at the Ohio State University Comprehensive Cancer Center.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors